These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 29462398)

  • 1. Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
    Fiorino G; Ruiz-Argüello MB; Maguregui A; Nagore D; Correale C; Radice S; Gilardi D; Allocca M; Furfaro F; Martínez A; Danese S
    Inflamm Bowel Dis; 2018 Feb; 24(3):601-606. PubMed ID: 29462398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
    Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Graziani MG; Lorenzetti R; Luzza F; Paese P; Penna A; Pica R; Pranzo G; Rodinò S; Scarcelli A; Zampaletta C; Brozzi L; Cicerone C; Cocco A; De' Angelis G; Donnarumma L; Fiorella S; Iannelli C; Larussa T; Le Grazie M; Luppino I; Meucci C; FaggianI R; Pagnini C; Perazzo P; Rodriguez-Castro KI; Sacco R; Sebkova L; Serio M; De Monti A; Picchio M; Napolitano D; Schiavoni E; Turchini L; Scaldaferri F; Pugliese D; Guidi L; Laterza L; Privitera G; Pizzoferrato M; Lopetuso LR; Armuzzi A; Elisei W; Maconi G; Papa A
    Expert Opin Biol Ther; 2022 Feb; 22(2):313-320. PubMed ID: 34904510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.
    Mazza S; Piazza O Sed N; Conforti FS; Fascì A; Rimondi A; Marinoni B; Casini V; Ricci C; Munari F; Pirola L; Invernizzi P; Girelli C; Lupinacci G; Pastorelli L; Cavallaro F; Ferraris L; Colucci A; Amato A; Eugenio Tontini G; Vecchi M; Fiorino G; Caprioli F
    Clin Transl Sci; 2022 Jan; 15(1):172-181. PubMed ID: 34523800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.
    Goncalves J; Santos M; Acurcio R; Iria I; Gouveia L; Matos Brito P; Catarina Cunha-Santos A; Barbas A; Galvão J; Barbosa I; Aires da Silva F; Alcobia A; Cavaco M; Cardoso M; Delgado Alves J; Carey JJ; Dörner T; Eurico Fonseca J; Palmela C; Torres J; Lima Vieira C; Trabuco D; Fiorino G; Strik A; Yavzori M; Rosa I; Correia L; Magro F; D'Haens G; Ben-Horin S; Lakatos PL; Danese S
    Aliment Pharmacol Ther; 2018 Sep; 48(5):507-522. PubMed ID: 29873091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
    Ben-Horin S; Yavzori M; Benhar I; Fudim E; Picard O; Ungar B; Lee S; Kim S; Eliakim R; Chowers Y
    Gut; 2016 Jul; 65(7):1132-8. PubMed ID: 25897019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
    Radin M; Sciascia S; Roccatello D; Cuadrado MJ
    BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
    Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G
    PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
    Trystram N; Abitbol V; Tannoury J; Lecomte M; Assaraf J; Malamut G; Gagnière C; Barré A; Sobhani I; Chaussade S; Amiot A
    Aliment Pharmacol Ther; 2021 Apr; 53(8):887-899. PubMed ID: 33647174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.
    Ruiz-Argüello MB; Maguregui A; Ruiz Del Agua A; Pascual-Salcedo D; Martínez-Feito A; Jurado T; Plasencia C; Balsa A; Llinares-Tello F; Rosas J; Torres N; Martínez A; Nagore D
    Ann Rheum Dis; 2016 Sep; 75(9):1693-6. PubMed ID: 26965981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An in vitro comparison of four different immunoassays for the monitoring of Infliximab biosimilars drug levels.
    Neveu B; Kunst A; Prosser C; Robitaille R
    Clin Biochem; 2020 Apr; 78():58-62. PubMed ID: 31982376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.
    Smits LJT; van Esch AAJ; Derikx LAAP; Boshuizen R; de Jong DJ; Drenth JPH; Hoentjen F
    Inflamm Bowel Dis; 2019 Jan; 25(1):172-179. PubMed ID: 29947795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
    Macaluso FS; Fries W; Viola A; Centritto A; Cappello M; Giuffrida E; Privitera AC; Piccillo G; Magnano A; Vinci E; Vassallo R; Trovatello A; Belluardo N; Giangreco E; Camilleri S; Garufi S; Bertolami C; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Orlando A
    Inflamm Bowel Dis; 2021 Jan; 27(2):182-189. PubMed ID: 32083291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort.
    Gros B; Plevris N; Constantine-Cooke N; Lyons M; O'Hare C; Noble C; Arnott ID; Jones GR; Lees CW; Derikx LAAP
    United European Gastroenterol J; 2023 Mar; 11(2):179-188. PubMed ID: 36802176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.
    Reinisch W; Jahnsen J; Schreiber S; Danese S; Panés J; Balsa A; Park W; Kim J; Lee JU; Yoo DH
    BioDrugs; 2017 Jun; 31(3):223-237. PubMed ID: 28497221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease.
    Lovero R; Losurdo G; La Fortezza RF; Terracciano F; Biscaglia G; Martino G; Nardella M; Di Leo A; Principi M; Andriulli A; Bossa F
    Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):201-207. PubMed ID: 33369956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.